XNCR

Xencor Inc

29.82

Oct 30 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: JANX ZYME MGNX CGEM GMAB IMNM ABCL INBX CTMX ADAG

| Held by: IJR VTI IWM XBI VXF IWN SPSM IJS IBB XSMO

Index	RUT
Market Cap	2.22B
Enterprise Value	1.93B
Income	-163.32M
Sales	104.97M
Book/sh	6.77
Cash/sh	6.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	260
IPO	Dec 03, 2013

P/E	-
Forward P/E	-
PEG	-
P/S	21.12
P/B	4.40
P/C	4.86
P/FCF	-
EV/EBITDA	-
EV/Sales	18.39
Quick Ratio	6.39
Current Ratio	6.39
Debt/Eq	0.34
LT Debt/Eq	0.28
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-3.34
EPS next Q	-0.33
EPS this Y	-142.11%
EPS next Y	-11.20%
EPS next 5Y	-
EPS past 3/5Y	-10.21% -0.43%
Sales past 3/5Y	-8.62% 0.47%
EPS Y/Y TTM	10.25%
Sales Y/Y TTM	-28.56%
EPS Q/Q	30.99%
Sales Q/Q	17.46%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	63.82% 171.16%

Insider Own	5.87%
Insider Trans	-0.69%
Inst Own	110.08%
Inst Trans	-4.86%
ROA	-20.36%
ROE	-29.07%
ROIC	-25.44%
Gross Margin	90.30%
Oper. Margin	-205.84%
Profit Margin	-155.59%
SMA20	15.88%
SMA50	15.85%
SMA200	75.87%
Trades

Shs Outstand	74.33M
Shs Float	69.99M
Short Float	17.53%
Short Ratio	8.25
Short Interest	12.27M
52W High	33.60 -11.25%
52W Low	10.38 187.42%
Volatility	8.23% 6.44%
ATR (14)	1.82
RSI (14)	67.97
Beta	0.79
Rel Volume	0.00
Avg Volume	1.49M
Volume	0

Perf Week	18.43%
Perf Month	20.39%
Perf Quarter	53.71%
Perf Half Y	134.99%
Perf YTD	94.77%
Perf Year	111.04%
Perf 3Y	73.07%
Perf 5Y	-24.62%
Perf 10Y	44.13%
Recom	1.36
Target Price	41.58
Prev Close	29.82
Price	29.82
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$41.58

Implied Upside

+39.4%

Analysts14incl. previous ratings

Rating Distribution12 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 30, 2026	Resumed	WWells Fargo	Overweight	$55	+84.4%
Mar 24, 2026	Downgrade	JJP Morgan	Overweight → Neutral	$13	-56.4%
Nov 24, 2025	Initiated	TTruist	Buy
Oct 29, 2025	Upgrade	BBarclays	Underweight → Overweight	$23	-22.9%
Sep 17, 2025	Resumed	BBarclays	Underweight	$6	-79.9%
Sep 03, 2025	Downgrade	BBofA Securities	Buy → Neutral	$12	-59.8%
Apr 21, 2025	Initiated	WWilliam Blair	Outperform
Dec 12, 2024	Initiated	WWells Fargo	Overweight	$37	+24.1%
Dec 02, 2024	Upgrade	PPiper Sandler	Neutral → Overweight	$20 → $30	+0.6%
Apr 16, 2024	Reiterated	BBTIG Research	Buy	$56 → $38	+27.4%
Feb 28, 2024	Downgrade	PPiper Sandler	Overweight → Neutral	$37 → $24	-19.5%
May 19, 2023	Initiated	BBofA Securities	Buy	$42	+40.8%
Dec 06, 2022	Initiated	CCowen	Outperform
Oct 13, 2022	Upgrade	RRaymond James	Outperform → Strong Buy	$58	+94.5%
Sep 21, 2022	Initiated	JJP Morgan	Overweight	$37	+24.1%
Jul 06, 2022	Resumed	CCanaccord Genuity	Buy	$50	+67.7%
Feb 11, 2022	Initiated	BBMO Capital Markets	Outperform	$54	+81.1%
Jan 21, 2022	Initiated	SSMBC Nikko	Outperform	$60	+101.2%
Dec 15, 2021	Initiated	HH.C. Wainwright	Buy	$61	+104.6%
Oct 15, 2021	Resumed	BBTIG Research	Buy	$56	+87.8%

Oct-26-26 12:08PM	Xencor shares jump as kidney cancer drug data support Phase 3 plans (Proactive) +15.89%
11:21AM	Xencor stock surges on positive cancer drug trial data (Investing.com)
Oct-25-26 04:35AM	Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors (Business Wire)
Oct-19-26 07:01AM	Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Oct-01-26 04:26PM	Raymond James Updates Healthcare Top Picks for October (Investing.com)
04:01PM	Loading…
Sep-02-26 04:01PM	Xencor to Present at the 2026 Cantor Global Healthcare Conference (Business Wire)
Aug-05-26 04:19PM	Xencor: Q2 Earnings Snapshot (Associated Press)
04:01PM	Xencor Reports Second Quarter 2026 Financial Results (Business Wire)
Jul-29-26 04:01PM	Xencor to Receive $105 Million From Alexion to Resolve Ultomiris U.S. Royalty Matter (Business Wire) +10.04%
Jul-17-26 09:11AM	Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire) +16.86%
Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
May-18-26 08:34AM	The Biology Came First. (Business Wire)
May-06-26 04:08PM	Xencor: Q1 Earnings Snapshot (Associated Press) -5.38%
04:01PM	Xencor Reports First Quarter 2026 Financial Results (Business Wire)
08:01AM	Loading…
May-04-26 08:01AM	Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW (Business Wire) +5.28%
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 06:00AM	Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor (Benzinga) -12.40%
Mar-04-26 04:01PM	Xencor Announces Change to Ultomiris Royalty Revenue Forecast (Business Wire) +5.99%
Feb-25-26 08:05PM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +13.11%
04:19PM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-23-26 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Jan-30-26 12:24AM	Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage (Insider Monkey)
Jan-08-26 08:01AM	Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones (Business Wire) -5.08%
Dec-09-25 07:00AM	Xencor Announces Extension of U.S. Patent Term on Certain Xtend Antibodies (Business Wire)
Nov-10-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire) +8.22%
Nov-05-25 05:35PM	Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:47PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2025 Financial Results (Business Wire)
06:08AM	Loading…
06:08AM	Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner (TipRanks)
Nov-04-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-24-25 12:30PM	Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma (Business Wire) +7.05%
Oct-21-25 08:01AM	Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma (Business Wire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily) +6.03%
Oct-14-25 12:45PM	Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Business Wire) -10.96%
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
Sep-18-25 10:05AM	Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks) +8.43%
Sep-08-25 12:30AM	RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating (Insider Monkey)
Aug-27-25 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Aug-08-25 09:05AM	Xencor price target lowered to $26 from $31 at Wedbush (TipRanks)
Aug-06-25 05:35PM	Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.79%
04:36PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 04:01PM	Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors (Business Wire)
07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
May-07-25 05:30PM	Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -5.61% +10.08%
04:26PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports First Quarter 2025 Financial Results (Business Wire)
May-01-25 10:01AM	Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-29-25 04:01PM	Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease (Business Wire)
Apr-11-25 10:15AM	Xencor, Inc.: No Major Near Term Catalysts (Seeking Alpha) +7.83%
Apr-10-25 12:00PM	Xencor (XNCR) Upgraded to Buy: Here's Why (Zacks) -10.10%
Mar-13-25 04:01PM	Xencor Appoints Todd Simpson to Board of Directors (Business Wire)
Feb-27-25 09:15AM	Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:15AM	Xencor: Q4 Earnings Snapshot (Associated Press Finance)
08:01AM	Xencor Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 09:35AM	Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-21-25 09:35AM	Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround (Zacks) +6.29%
Jan-20-25 09:35AM	After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR) (Zacks)
Jan-15-25 09:35AM	Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks (Zacks)
Jan-14-25 12:00PM	Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -5.68%
Dec-12-24 12:00PM	All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy (Zacks)
Dec-04-24 09:55AM	Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet (Zacks)
Nov-26-24 04:01PM	Xencor to Participate at Upcoming Investor Conferences (Business Wire)
Nov-18-24 09:55AM	Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade (Zacks)
Nov-14-24 09:55AM	Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
Nov-06-24 05:15PM	Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.39%
04:11PM	Xencor: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 07:00AM	Xencor Doses First Subject in Phase 1/2 Study of XmAb942 in Development for Patients with Inflammatory Bowel Disease (Business Wire)
Nov-01-24 09:55AM	Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? (Zacks)
Oct-29-24 10:01AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Xencor Inc Holdings (GuruFocus.com)
Oct-16-24 09:55AM	Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know (Zacks)
Oct-10-24 08:09AM	Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases (Business Wire)
Oct-04-24 08:01AM	Xencor Announces Upcoming Change to Board of Directors (Business Wire)
Sep-12-24 04:01PM	Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire)
04:55AM	Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains? (Zacks)
Sep-11-24 06:31AM	Xencor Announces Pricing of $175 Million Public Offering of Common Stock (Business Wire) +10.45%
Sep-10-24 04:01PM	Xencor Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-09-24 07:31AM	Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs (Business Wire) +22.93%
Sep-06-24 08:01AM	Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024 (Business Wire)
Aug-05-24 09:55PM	XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) -7.30%
05:15PM	Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Xencor: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xencor Reports Second Quarter 2024 Financial Results (Business Wire)
Jun-13-24 08:01AM	Xencor Regains CD20 x CD3 Bispecific T-Cell Engager (Business Wire)
May-10-24 01:45PM	Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates (GuruFocus.com)
06:20AM	Wedbush Adjusts Xencor's Price Target to $36 From $34, Keeps Outperform Rating (MT Newswires)
May-09-24 11:54PM	XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:18PM	Xencor: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	Xencor Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 10:00AM	Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-03-24 07:01PM	Insider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares (GuruFocus.com)
May-02-24 03:31AM	Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last? (Zacks)
Apr-09-24 08:01AM	Xencor Appoints Bart Cornelissen as Chief Financial Officer (Business Wire)
Mar-08-24 05:01PM	Insider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR) (GuruFocus.com)
Mar-07-24 05:00PM	Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor Inc (XNCR) (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feigal Ellen	Director	Jun 18 '26	Sale	13.06	6,843	89,370	12,340	Jun 22 04:01 PM
Feigal Ellen	Director	Jun 18 '26	Proposed Sale	13.06	6,843	89,370		Jun 18 09:38 AM
GORMAN KEVIN CHARLES	Director	Jun 15 '26	Sale	12.31	7,527	92,657	11,378	Jun 17 04:02 PM
GUSTAFSON KURT A	Director	Jun 15 '26	Sale	12.31	5,474	67,385	14,709	Jun 17 04:01 PM
RANIERI RICHARD J	Director	Jun 15 '26	Sale	12.31	5,474	67,385	13,709	Jun 17 04:01 PM
Montgomery Alan Bruce	Director	Jun 15 '26	Sale	12.31	5,064	62,338	15,547	Jun 17 04:01 PM
Montgomery Alan Bruce	Director	Jun 15 '26	Proposed Sale	12.31	5,064	62,338		Jun 15 11:36 AM
RANIERI RICHARD J	Director	Jun 15 '26	Proposed Sale	12.31	5,474	67,385		Jun 15 10:57 AM
GUSTAFSON KURT A	Director	Jun 15 '26	Proposed Sale	12.31	5,474	67,385		Jun 15 10:44 AM
GORMAN KEVIN CHARLES	Director	Jun 15 '26	Proposed Sale	12.31	7,527	92,657		Jun 15 09:44 AM
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Apr 10 '26	Sale	12.29	3,499	42,990	75,898	Apr 13 04:01 PM
Cornelissen Bart Jan	Officer	Apr 10 '26	Proposed Sale	12.29	3,499	42,990		Apr 10 03:16 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 05 '26	Sale	11.25	4,118	46,309	266,333	Mar 09 04:07 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 06 '26	Sale	11.02	2,502	27,571	263,831	Mar 09 04:07 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 05 '26	Sale	11.25	3,244	36,480	78,685	Mar 09 04:06 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 06 '26	Sale	11.02	1,767	19,472	76,918	Mar 09 04:06 PM
Cornelissen Bart Jan	SR. VICE PRESIDENT & CFO	Mar 05 '26	Sale	11.25	2,517	28,305	79,397	Mar 09 04:06 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 05 '26	Sale	11.25	14,870	167,221	552,922	Mar 09 04:06 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 06 '26	Sale	11.02	6,606	72,796	546,316	Mar 09 04:06 PM
Eckert Celia	Officer	Mar 06 '26	Proposed Sale	11.02	1,767	19,472		Mar 06 04:00 PM
Dahiyat Bassil I	Officer	Mar 06 '26	Proposed Sale	11.02	6,606	72,796		Mar 06 03:55 PM
Desjarlais John R	Officer	Mar 06 '26	Proposed Sale	11.02	2,502	27,571		Mar 06 03:39 PM
Eckert Celia	Officer	Mar 05 '26	Proposed Sale	11.25	3,244	36,480		Mar 05 04:30 PM
Dahiyat Bassil I	Officer	Mar 05 '26	Proposed Sale	11.25	14,870	167,221		Mar 05 04:26 PM
Cornelissen Bart Jan	Officer	Mar 05 '26	Proposed Sale	11.25	2,517	28,305		Mar 05 04:18 PM
Desjarlais John R	Officer	Mar 05 '26	Proposed Sale	11.25	4,118	46,309		Mar 05 04:14 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Mar 03 '26	Sale	11.90	2,663	31,677	270,451	Mar 04 07:43 PM
Eckert Celia	SVP, GENERAL COUNSEL	Mar 03 '26	Sale	11.90	1,492	17,747	81,929	Mar 04 07:42 PM
Dahiyat Bassil I	PRESIDENT & CEO	Mar 03 '26	Sale	11.90	6,758	80,387	567,792	Mar 04 07:42 PM
Dahiyat Bassil I	Officer	Mar 03 '26	Proposed Sale	11.90	6,758	80,387		Mar 03 04:27 PM
Eckert Celia	Officer	Mar 03 '26	Proposed Sale	11.90	1,492	17,747		Mar 03 03:32 PM
Desjarlais John R	Officer	Mar 03 '26	Proposed Sale	11.90	2,663	31,677		Mar 03 03:15 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Jan 23 '26	Option Exercise	12.51	5,322	66,578	248,207	Jan 26 04:01 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Option Exercise	12.51	73,367	917,821	309,941	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 22 '25	Option Exercise	12.51	6,311	78,951	242,885	Dec 23 04:02 PM
Desjarlais John R	SR. VICE PRESIDENT & CSO	Dec 19 '25	Sale	15.72	73,367	1,153,329	236,574	Dec 23 04:02 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Option Exercise	12.51	114,377	1,430,856	581,012	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 22 '25	Option Exercise	12.51	10,624	132,906	477,259	Dec 23 04:01 PM
Dahiyat Bassil I	PRESIDENT & CEO	Dec 19 '25	Sale	15.71	114,377	1,796,863	466,635	Dec 23 04:01 PM
Desjarlais John R	Officer	Dec 19 '25	Proposed Sale	15.72	73,367	1,153,517		Dec 19 04:19 PM
Dahiyat Bassil I	Officer	Dec 19 '25	Proposed Sale	15.71	114,377	1,796,943		Dec 19 04:13 PM

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Pasadena, CA.

Co-FounderDr. Bassil I. Dahiyat Ph.D.

Senior VP & CFOMr. Bart Jan Cornelissen

Executive VP of Research & Chief Scientific OfficerDr. John R. Desjarlais Ph.D.

Senior VPMs. Celia E. Eckert J.D.

Associate Director and Head of Corporate Communications & Investor RelationsMr. Charles Liles

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XNCR

Xencor Inc

Upgrade your Finviz experience